Journal Article Review Epublish 14 citations
PubMed: 36831044 DOI: 10.3390/biomedicines11020508
Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC.
Biomedicines 11(2)
Authors: Kah Yee Goh, Terence You De Cheng, Su Chin Tham, Darren Wan-Teck Lim
Affiliations
- Division of Medical Oncology, National Cancer Centre Singapore, 11 Hospital Crescent, Singapore 169610, Singapore.
- Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Proteos, Singapore 138673, Singapore.
- Office of Academic and Clinical Development, Duke-NUS Medical School, Singapore 169857, Singapore.
Abstract
Non-small cell lung cancer (NSCLC) constitutes the majority of the lung cancer population and the prognosis is poor. In recent years, immunotherapy has become the standard of care for advanced NSCLC patients as numerous trials demonstrated that immune checkpoint inhibitors (ICI) are more efficacious than conventional chemotherapy. However, only a minority of NSCLC patients benefit from this treatment. Therefore, there is an unmet need for biomarkers that could accurately predict response to immunotherapy. Liquid biopsy allows repeated sampling of blood-based biomarkers in a non-invasive manner for the dynamic monitoring of treatment response. In this review, we summarize the efforts and progress made in the identification of circulating biomarkers that predict immunotherapy benefit for NSCLC patients. We also discuss the challenges with future implementation of circulating biomarkers into clinical practice.
MeSH
Lung, Neoplasms, Carcinoma, Non-Small-Cell Lung, Biomarkers, Immunotherapy, Lung Neoplasms, Therapeutics, Liquid Biopsy
Cited by
- Very Early Health Technology Assessment for Potential Predictive Biomarkers in the Treatment of Advanced Non-Small Cell Lung Cancer. Pharmacoecon Open, 2025
- The prognostic role of salivary miRNAs in oral squamous cell carcinoma: technical challenges and clinical perspectives. Acta Otorhinolaryngol Ital, 2024
- Blood biomarkers to predict the efficacy of neoadjuvant chemo-immunotherapy in non-small cell lung cancer patients. Transl Lung Cancer Res, 2024
- Prognostic and clinicopathological role of soluble programmed cell death ligand-1 in patients with diffuse large B-cell lymphoma: a meta-analysis. Front Oncol, 2025
- Plasmacytoid Dendritic Cell, Slan-Monocyte and Natural Killer Cell Counts Function as Blood Cell-Based Biomarkers for Predicting Responses to Immune Checkpoint Inhibitor Monotherapy in Non-Small Cell Lung Cancer Patients. Cancers (Basel), 2023
- Biomarkers for immunotherapy resistance in non-small cell lung cancer. Front Oncol, 2025
- Circulating Tumor Cell-Free DNA as Prognostic Biomarker in Non-Small Cell Lung Cancer Patients Undergoing Immunotherapy: The CORELAB Experience. Int J Mol Sci, 2025